NovoCure Limited NVCR R2K
Healthcare · Medical Devices · Switzerland
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
READ MORE ›$17.04
-10.83% 1Y
Market & Price
Market Cap
$1.97B
Current Price
$17.04
High / Low (52W)
$19.11 / $10.03
Beta
0.90
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$2.85
Price to Book
5.97
P/S
2.93
EV/EBITDA
-10.69
Dividend Yield
-
Profitability & Returns
ROCE
-20.52%
ROE
-49.96%
ROA
-11.06%
Profit Margin
-25.66%
Op Margin
-38.73%
EPS (Latest Qtr)
$-0.62
EPS (TTM)
$-1.53
Balance Sheet & Liquidity
Debt/Equity
0.71
Quick Ratio
2.66
Current Ratio
2.90
Debt
$234.94M
Total Assets
$804.33M
Current Assets
$646.73M
Working Capital
$423.50M
Ownership
Promoter Holding
9.98%
Chg in Prom Hold
-
FII / Inst Holding
87.44%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$1.78B
Total Revenue (TTM)
$674.41M
EBITDA
$-166.22M
Free Cash Flow
$5.08M
Operating Cash Flow
$-26.88M
Shares Outstanding
115.82M
Gross Margin
75.45%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
6.81%
Profit 5Y
-15.74%
Revenue (YoY)
12.30%
Earnings (YoY)
-
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -15.7% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NVCR NovoCure Limited R2K | 17.04 | - | $1.97B | - | -20.52% | -49.96% | 6.81% | -15.74% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 13.05M | 17.92M | 21.67M | 30.24M | 34.88M | 38.38M | 50.11M | 53.66M | 52.12M | 61.51M | 64.76M | 69.67M | 73.31M | 86.71M | 92.06M | 99.23M | 101.83M | 115.92M | 132.66M | 143.95M | 134.69M | 133.52M | 133.61M | 133.21M | 137.55M | 140.87M | 131.00M | 128.43M | 122.18M | 126.05M | 127.32M | 138.50M | 150.36M | 155.09M | 154.99M | 158.81M | 167.20M | 174.35M | 174.06M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 38.52M | 41.47M | 44.73M | 42.16M | 38.93M |
| Gross Profit | 6.08M | 5.07M | 1.71M | 10.56M | 19.27M | 23.22M | 25.22M | 34.96M | 38.02M | 33.89M | 41.68M | 45.81M | 46.65M | 53.49M | 65.61M | 69.16M | 74.45M | 77.33M | 90.45M | 104.27M | 115.82M | 108.31M | 104.92M | 103.40M | 103.53M | 109.82M | 112.36M | 101.25M | 99.54M | 92.57M | 92.03M | 95.23M | 104.81M | 115.70M | 119.72M | 116.47M | 117.33M | 122.47M | 132.19M | 135.13M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 154.34M | 156.85M | 158.50M | 172.59M | 202.55M |
| Operating Income | -30.61M | -31.94M | -37.24M | -28.27M | -17.88M | -13.37M | -15.53M | -5.92M | -4.51M | -12.68M | -7.08M | -5.25M | -8.66M | -6.12M | 1.20M | 3.85M | 153.00K | -3.38M | 6.67M | 15.02M | 12.09M | -88.00K | -12.29M | -8.55M | -23.40M | -806.00K | -21.13M | -24.61M | -42.98M | -60.25M | -62.66M | -58.24M | -41.52M | -33.58M | -32.09M | -37.87M | -39.52M | -36.02M | -40.39M | -67.42M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -34.54M | -36.08M | -32.36M | -1.59M | -63.30M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -30.30M | -34.98M | -30.02M | -40.95M | -69.26M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.02M | 5.16M | 7.25M | -16.45M | 1.88M |
| Net Income | -32.93M | -35.44M | -40.61M | -33.63M | -22.17M | -18.05M | -21.17M | -11.50M | -10.95M | -20.72M | -15.51M | -11.69M | -15.63M | -12.15M | -1.27M | 1.93M | 4.26M | 3.95M | 1.66M | 9.28M | 4.92M | -4.13M | -14.64M | -13.12M | -26.46M | -4.65M | -24.01M | -26.58M | -37.30M | -53.06M | -57.42M | -49.48M | -38.76M | -33.38M | -30.57M | -34.32M | -40.14M | -37.27M | -24.50M | -71.14M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -0.13 | - | -0.13 | -0.01 | 0.02 | 0.04 | 0.04 | 0.02 | 0.09 | 0.04 | -0.04 | -0.14 | -0.13 | -0.25 | -0.04 | -0.23 | -0.25 | -0.36 | -0.50 | -0.54 | -0.46 | -0.36 | -0.31 | -0.28 | -0.31 | -0.36 | -0.33 | -0.22 | -0.62 |
| R&D Expense | - | 11.45M | 11.32M | 10.23M | - | 9.41M | 9.37M | 9.27M | - | 11.10M | 11.36M | 13.07M | - | 17.04M | 19.45M | 18.77M | - | 25.27M | 29.92M | 32.82M | - | 45.92M | 50.31M | 48.14M | - | 42.23M | 57.08M | 51.96M | - | 59.70M | 55.43M | 53.62M | 51.60M | 54.95M | 51.88M | 53.78M | 55.83M | 54.03M | - | 58.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 82.89M | 177.03M | 248.07M | 351.32M | 494.37M | 535.03M | 537.84M | 509.34M | 605.22M | 655.35M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 114.87M | 128.28M | 137.18M | 166.88M |
| Gross Profit | 3.35M | 5.45M | 12.48M | 36.61M | 121.42M | 168.02M | 262.71M | 387.87M | 420.15M | 422.97M | 381.06M | 468.04M | 488.47M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 512.50M | 613.93M | 638.53M | 642.27M |
| Operating Income | -64.46M | -80.16M | -104.00M | -115.32M | -39.33M | -33.67M | -914.00K | 30.40M | -44.33M | -89.52M | -232.87M | -170.50M | -153.80M |
| EBITDA | - | - | - | - | - | - | - | - | - | -67.89M | -177.45M | -109.58M | -104.56M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 3.33M | 3.32M | 10.34M | 17.04M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -81.85M | -191.74M | -131.16M | -136.25M |
| Tax Provision | - | - | - | - | - | - | - | - | - | 10.69M | 15.30M | 37.47M | -23.00K |
| Net Income | -77.37M | -80.68M | -111.58M | -131.84M | -61.66M | -63.56M | -7.23M | 19.81M | -58.35M | -92.53M | -207.04M | -168.63M | -136.23M |
| Diluted EPS | - | - | - | - | - | -0.69 | -0.07 | 0.18 | -0.56 | -0.88 | -1.95 | -1.56 | -1.22 |
| R&D Expense | 34.80M | 40.38M | 43.75M | 41.47M | 38.10M | 50.57M | 79.00M | 132.01M | 201.30M | 206.09M | 223.06M | 209.65M | 224.54M |
Compounded Sales Growth
| 5 Years: | 6.81% |
| 1 Year: | 12.30% |
Compounded Profit Growth
| 5 Years: | -15.74% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -10.83% |
| 6 Months: | +34.81% |
| 3 Months: | +24.65% |
| 1 Month: | +42.83% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 117.88M | 307.34M | 282.08M | 265.30M | 339.79M | 479.45M | 1.05B | - | 1.19B | 1.15B | 1.24B | 804.33M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 1.11B | 1.03B | 1.11B | 646.73M |
| Cash & Equivalents | 34.89M | 175.89M | 57.61M | 119.42M | 99.78M | 78.59M | 140.62M | 177.32M | 234.67M | - | 115.33M | 240.82M | 163.77M | 93.55M |
| Inventory | - | - | - | - | - | - | - | - | - | - | 29.38M | 38.15M | 35.09M | 41.11M |
| Receivables | - | - | - | - | - | - | - | - | - | - | 86.26M | 61.22M | 74.23M | 89.44M |
| Total Liabilities | - | - | 20.00M | 56.52M | 139.74M | 151.73M | 227.53M | 261.66M | 575.46M | - | 750.48M | 783.63M | 880.61M | 463.86M |
| Current Liabilities | - | - | 17.67M | 28.63M | 36.88M | 50.20M | 64.56M | 86.31M | 113.61M | - | 158.78M | 179.12M | 756.39M | 223.23M |
| Long Term Debt | - | - | 0 | 23.10M | 96.23M | 97.34M | 149.27M | 149.42M | 429.90M | - | 565.51M | 568.82M | 97.30M | 195.05M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 584.27M | 604.56M | 683.34M | 248.35M |
| Total Equity | 49.42M | 171.78M | 97.88M | 250.82M | 142.34M | 113.56M | 112.26M | 217.79M | 476.53M | - | 441.17M | 362.50M | 360.18M | 340.47M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 105.05M | 107.08M | 108.52M | 112.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -107.59M | -33.13M | -1.86M | 26.62M | 99.15M | 82.76M | 30.79M | -73.34M | -26.37M | -49.03M |
| Investing Cash Flow | - | - | - | 13.00M | 8.63M | -5.49M | -51.67M | -472.85M | -144.83M | -139.96M | 184.15M | -140.24M | 437.28M |
| Financing Cash Flow | - | - | - | 75.12M | 5.17M | 69.37M | 61.68M | 440.21M | 25.70M | 15.49M | 15.79M | 90.31M | -451.34M |
| Capital Expenditure | -2.20M | -849.00K | -4.67M | -5.67M | -7.37M | -6.71M | -10.48M | -14.97M | -24.17M | -21.36M | -27.09M | -42.85M | -26.65M |
| Free Cash Flow | - | - | - | -113.27M | -40.50M | -8.58M | 16.14M | 84.18M | 58.59M | 9.43M | -100.43M | -69.22M | -75.68M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | -93.68M | 126.60M | -76.30M | -63.10M |
| Share Buybacks | - | - | 5.00K | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | - | - | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 44.2% | 68.6% | 67.7% | 74.8% | 78.5% | 78.5% | 78.6% | 74.8% | 77.3% | 74.5% |
| Operating Margin % | - | - | - | -139.1% | -22.2% | -13.6% | -0.3% | 6.1% | -8.3% | -16.6% | -45.7% | -28.2% | -23.5% |
| Net Margin % | - | - | - | -159.1% | -34.8% | -25.6% | -2.1% | 4.0% | -10.9% | -17.2% | -40.6% | -27.9% | -20.8% |
| ROE % | -45.0% | -82.4% | -44.5% | -92.6% | -54.3% | -56.6% | -3.3% | 4.2% | - | -21.0% | -57.1% | -46.8% | -40.0% |
| ROCE % | - | -80.0% | -37.3% | -47.0% | -18.3% | -12.2% | -0.2% | 3.2% | - | -8.7% | -24.1% | -35.2% | -26.5% |
Shareholding Pattern
Insiders
9.98%
Institutions
87.44%
Public Float
97.13%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.74% | 17.07M | $290.86M |
| 2 | Blackrock Inc. | 11.39% | 13.19M | $224.82M |
| 3 | Soleus Capital Management, L.P. | 9.06% | 10.49M | $178.79M |
| 4 | Vanguard Portfolio Management LLC | 5.40% | 6.25M | $106.53M |
| 5 | Vanguard Capital Management LLC | 4.04% | 4.68M | $79.78M |
| 6 | Morgan Stanley | 3.92% | 4.54M | $77.39M |
| 7 | Wells Fargo & Company | 2.55% | 2.95M | $50.29M |
| 8 | State Street Corporation | 2.21% | 2.56M | $43.65M |
| 9 | Geode Capital Management, LLC | 2.17% | 2.51M | $42.80M |
| 10 | Quantinno Capital Management, LP | 2.15% | 2.49M | $42.38M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NVCR
No recent headlines available.